Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Feb 11, 2021 and accepted by EDGAR at Feb 11, 2021, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-10-01 to 2020-12-31 | $1.63bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2020-01-01 to 2020-12-31 | $6.21bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-10-01 to 2020-12-31 | $203.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | $736.3m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2020-10-01 to 2020-12-31 | $466.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $1.83bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-10-01 to 2020-12-31 | $211.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2020-01-01 to 2020-12-31 | $770.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-10-01 to 2020-12-31 | $745.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2020-01-01 to 2020-12-31 | $2.86bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-10-01 to 2020-12-31 | $16.3m | us-gaap:InterestExpense |
| Interest expense | 12 months2020-01-01 to 2020-12-31 | $58.2m | us-gaap:InterestExpense |
| Income tax | 3 months2020-10-01 to 2020-12-31 | $284.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $405.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-10-01 to 2020-12-31 | $604.2m | us-gaap:NetIncomeLoss |
| Net income | 12 months2020-01-01 to 2020-12-31 | $2.71bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-10-01 to 2020-12-31 | $2.30 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | $10.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-10-01 to 2020-12-31 | $2.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2020-01-01 to 2020-12-31 | $10.44 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-10-01 to 2020-12-31 | 263,106,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2020-01-01 to 2020-12-31 | 263,396,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | $3.25bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $259.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2020-01-01 to 2020-12-31 | $539.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-12-31 | $5.99bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $8.13bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $11.75bn | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $1.88bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $3.06bn | us-gaap:Liabilities |
Source: SEC EDGAR, the filing index for accession 0000875320-21-000006. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.